DexCom, Inc. (DXCM)
DexCom, Inc. is a medical device company specializing in continuous glucose monitoring (CGM) systems for people with diabetes. Founded in 1999, the company develops innovative technologies that provide real-time glucose readings to help manage blood sugar levels more effectively. DexCom's products are used by patients and healthcare professionals worldwide to improve diabetes management and reduce complications associated with the condition.
Company News
Rosen Law Firm alerts DexCom investors about a securities class action lawsuit alleging unauthorized medical device design changes and misleading statements about product reliability and safety.
DexCom's stock has dropped to a 5-year low due to concerns about GLP-1 weight loss drugs potentially reducing demand for continuous glucose monitoring devices. Despite the decline, analysts suggest the stock might be undervalued and present a buying opportunity.
U.S. markets stabilized on Tuesday with subdued trading, awaiting a House vote on ending the government shutdown. Tech stocks experienced modest declines, while commodities like oil and silver showed gains.
The article highlights three stocks with potential dividend and growth opportunities in 2025: Schlumberger (SLB), General Electric Aerospace (GE), and DexCom (DXCM), each offering unique investment prospects in energy, aerospace, and medical technology sectors.
DexCom, Inc. is scheduled to release its second-quarter 2024 results on July 25. The company's revenues are expected to grow 19% year-over-year, driven by increased product volume and global awareness of its continuous glucose monitoring system. However, rising costs and competition may have weighed on its performance.
